ArticleCancer cell international2025
INHBA promotes chemoresistance in pancreatic cancer by enhancing CTPS1 stability and mediating pyrimidine metabolism.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGemcitabine is the primary chemotherapeutic agent used as a first-line treatment for pancreatic cancer (PC), underscoring its pivotal role in cancer treatment. This drug induces apoptosis through multiple mechanisms, with the disruption of cellular pyrimidine metabolism being a crucial mode of action. However, gemcitabine resistance significantly limits the long-term efficacy of PC treatments. Our study aimed to identify potential targets for gemcitabine sensitization.
methodsWe identified a gene set associated with pyrimidine metabolism through cluster analysis of The Cancer Genome Atlas Pancreatic Adenocarcinoma database. Intersecting this set of differentially upregulated genes in PC with normal tissues revealed inhibin βA (INHBA) as a gene related to pyrimidine metabolism. Quantitative reverse transcription-polymerase chain reaction, western blotting, and immunohistochemistry analyses confirmed INHBA overexpression in PC cells. INHBA's effects of INHBA on cell proliferation and chemoresistance in PC cells were validated in vitro using a colony counting kit-8 assay, drug sensitivity analysis, EdU incorporation, flow cytometry, and colony formation assay. The proliferation and chemoresistance promotion by INHBA in PC cells was validated in vivo using a mouse xenograft model. Downstream targets of INHBA were identified using immunoprecipitation mass spectrometry.
resultsINHBA, a pyrimidine metabolism-associated gene, was highly expressed in PC, and its expression correlated with gemcitabine resistance. INHBA interacts with cytidine triphosphate synthase 1 (CTPS1) and competitively inhibits SMAD Specific E3 Ubiquitin Protein Ligase 1 mediated ubiquitination, enhancing CTPS1 stability and promoting pyrimidine metabolism.
conclusionINHBA promotes gemcitabine resistance in PC by stabilizing CTPS1 and enhancing pyrimidine metabolism, making it a potential target for chemosensitization in PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.